Literature DB >> 21717076

Role of neurokinin-1 receptor in the initiation and maintenance of skin chronic inflammatory diseases.

Sherrie J Divito1, Adrian E Morelli, Adriana T Larregina.   

Abstract

To fulfill its immunologic functions, the skin is richly populated with dendritic cells (DCs), the most potent professional Ag-processing and Ag-presenting cells of the immune system. The immune-stimulatory and tolerogenic functions of skin DCs are regulated by the immune and neuroendocrine systems. Pro-inflammatory neuropeptides like substance P and calcitonin gene-related peptide secreted by cutaneous Aδ and C nerve fibers are the main initiators of neuro-inflammatory responses in the skin. Conversely, anti-inflammatory neuropeptides like the products of cleavage of proopiomelanocortin (α-melanocyte-stimulating hormone and adrenocorticotropic hormone) negatively regulate immune responses in the skin. Likewise, the control of immune responses against stimuli applied to the skin depends on the balance between the release and neutralization of pro-inflammatory and anti-inflammatory neuropeptides, a matter that has been somehow overlooked by the immunology field until recently.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717076     DOI: 10.1007/s12026-011-8219-9

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  90 in total

1.  PepPat, a pattern-based oligopeptide homology search method and the identification of a novel tachykinin-like peptide.

Authors:  Ying Jiang; Ge Gao; Gang Fang; Eric L Gustafson; Maureen Laverty; Yanbin Yin; Yong Zhang; Jingchu Luo; Jonathan R Greene; Marvin L Bayne; Joseph A Hedrick; Nicholas J Murgolo
Journal:  Mamm Genome       Date:  2003-05       Impact factor: 2.957

2.  Cloning of human preprotachykinin-I promoter and the role of cyclic adenosine 5'-monophosphate response elements in its expression by IL-1 and stem cell factor.

Authors:  J Qian; G Yehia; C Molina; A Fernandes; R Donnelly; D Anjaria; P Gascon; P Rameshwar
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

3.  Enhancement of phagocytosis - a newly found activity of substance P residing in its N-terminal tetrapeptide sequence.

Authors:  Z Bar-Shavit; R Goldman; Y Stabinsky; P Gottlieb; M Fridkin; V I Teichberg; S Blumberg
Journal:  Biochem Biophys Res Commun       Date:  1980-06-30       Impact factor: 3.575

4.  Noradrenergic and peptidergic innervation of the mouse femur bone marrow.

Authors:  Z Tabarowski; K Gibson-Berry; S Y Felten
Journal:  Acta Histochem       Date:  1996-11       Impact factor: 2.479

5.  Selective modulation of the natural killer activity of murine intestinal intraepithelial leucocytes by the neuropeptide substance P.

Authors:  K Croitoru; P B Ernst; J Bienenstock; I Padol; A M Stanisz
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

6.  Neurokinin type-1 receptor antagonist inhibits enhancement of T cell functions by substance P in normal and neuromanipulated capsaicin-treated rats.

Authors:  G Santoni; M C Perfumi; E Spreghini; S Romagnoli; M Piccoli
Journal:  J Neuroimmunol       Date:  1999-01-01       Impact factor: 3.478

7.  Substance P acts directly upon cloned B lymphoma cells to enhance IgA and IgM production.

Authors:  D W Pascual; J C Xu-Amano; H Kiyono; J R McGhee; K L Bost
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

8.  Molecular evidence that granuloma T lymphocytes in murine schistosomiasis mansoni express an authentic substance P (NK-1) receptor.

Authors:  G A Cook; D Elliott; A Metwali; A M Blum; M Sandor; R Lynch; J V Weinstock
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

9.  Human lymphocytes express substance P and its receptor.

Authors:  J P Lai; S D Douglas; W Z Ho
Journal:  J Neuroimmunol       Date:  1998-06-01       Impact factor: 3.478

10.  Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues.

Authors:  R S Metzgar; M J Borowitz; N H Jones; B L Dowell
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.